Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine if sulindac at a dose of 150 mg twice a
day for 12 months reduces breast density in postmenopausal women at elevated risk of breast
cancer when compared to a placebo control.